Bristol-Myers Squibb
New Jersey, USA
New Jersey, USA
Eric Simmons was born in New Hampshire and grew up in Portland, ME, USA. He received his B.S. in chemistry and Spanish from Tufts University in 2004 and completed his Ph.D. in organic chemistry with Prof. Richmond Sarpong at the University of California at Berkeley in 2009. He then conducted post-doctoral studies in the areas of organometallic chemistry and catalysis with Prof. John F. Hartwig at the University of Illinois at Urbana-Champaign. In 2011, he joined the Catalysis Research & Development Group in the process department at Bristol Myers Squibb in New Brunswick, NJ, USA. As a scientist at BMS, he was part of project teams that validated a Pd-cat. intramolecular direct arylation for the commercial synthesis of the HCV NS5B inhibitor beclabuvir (Ximency) and a Pd-cat. C-N coupling for the commercial synthesis of the Tyk2 inhibitor deucravactinib (Sotyktu). He has collaborated extensively with colleagues in both process and medicinal chemistry, as well as with various research groups in academia, in the discovery and mechanistic study of novel catalytic transformations. Eric is currently Associate Scientific Director and Catalysis Group lead in Chemical Process Development at BMS.